Introduction
============

A disease is considered rare when its low incidence becomes a problem to be added, making more difficult its accurate diagnosis and decreasing the interest in its research and the development of drugs for its treatment. According to the definition provided by the European Union, rare diseases are those with prevalence values lesser than 5/10,000 and leading patients to higher risk of death or chronic disability. Although it is difficult to estimate the exact number of rare diseases, most probably this number is within the range 6000--8000. More than 2000 rare diseases have already one or more genes assigned; see (<http://www.rdplatform.org>) and [@b1]. The greatest database on the subject, Orphanet (<http://www.orpha.net/consor/cgi-bin/index.php>) contains information on almost 6000 rare diseases. Therefore, although each rare disease is infrequent, altogether rare diseases affect to 6--8% of total population in developed countries. Currently, more than 30 millions of European citizens suffer from some kind of rare disease and are exposed to discriminatory medical care benefits. Different projects have been financed under the Programme for Community Action on Rare Diseases in 1999--2003; the EU Public Health Programme 2003--2007 and the second EU Health Programme 2008--2013 (<http://ec.europa.eu/health/rare_diseases/projects/cooperation/index_en.htm>).

A fundamental question arises: how to get access to this highly specialized and very reduced knowledge area where each described rare disease becomes an isolated particularity? A reasonable option could be the comparative study of analogies among different rare diseases (<http://www.orpha.net/consor/cgi-bin/Education_Home.php?lng=EN>). However, the low prevalence (the fact of being rare) is the only descriptor that---by definition---can be applied in any methodology for the systemic study of all or a group of rare diseases. This description based on low prevalence is crucial for the integration of medical policies in the framework of rare diseases, but on the other hand it contributes nothing to the molecular description of rare diseases and the physio-pathological relationships they could share. This is the current situation, in spite of the fact that next-generation sequencing technologies and exome analysis are making possible to identify molecular markers for some rare diseases [@b2].

The specification of classification systems able to order the collected information on a disease according to coherent categories and criteria plays an essential role in biomedical sciences. In particular, this is of paramount importance for the description and diagnosis of rare diseases and for the adoption of decisions concerning health care, clinical and therapeutical indications and derivation of patients to specialists. In this context, Orphanet and WHO (World Health Organization) are currently making important efforts for the future specification of the international classification of diseases ICD11 (<http://www.who.int/classifications/icd/revisionnews/en/>), which will include rare diseases for the first time [@b3]. Unfortunately, there is still a lack of a clinical identification accredited for this kind of diseases. In consequence, the search for information on rare diseases remains complex and diffuse.

Specific problems also arise from the usual way in which the scientific literature is written. Unfortunately, scientific literature does not use to identify rare diseases as such and the identifiers for them proposed (*i.e*. ORPHA or OMIM IDs) are scarcely mentioned. In consequence, the search of information on rare diseases through the primary sources of scientific documentation is not an easy task. In fact, the finding of common relationships among diseases depends mainly on the reduced and specialized area of knowledge that dominates each rare disease, a fact that severely limits the visibility of these relationships.

Far beyond the epidemiological, clinical and molecular studies and decision making in public health, the adoption of wider and more general and holistic approaches could become a new way to access to new knowledge in this area. The implementation of informatics resources to extract data from scientific literature and to analyze and enrich this information is currently contributing to the advancement of knowledge in biomedicine. This could be a powerful strategy to establish emerging sources of knowledge also in the specific field of rare diseases.

A systematic review and collection of relevant information contained in diverse sources of scientific information and documentation could provide new valuable, emergent information concerning rare diseases. In the present work, we apply this systemic approach to get a deeper insight on the current knowledge of angiogenesis-related rare diseases (A-RDs).

Angiogenesis, the formation of new vessels from the pre-existing vasculature, is one main mechanism of vascularisation during normal and specific physiological processes, such as embryonic development, growth, regeneration, wound healing and formation of *corpus luteum* and endometrium. Angiogenesis attracted wide interest in the scientific community when the pioneering hypothesis of Judah Folkman in 1971 that tumor progression and metastasis are dependent on angiogenesis (and, as such, cancer could be therapeutically attacked by inhibiting angiogenesis) began to be confirmed by experimental studies since the eighties [@b4]--[@b6]. In fact, inhibition of this process has become a major challenge in the development of new anticancer agents, with more than 40,000 scientific papers published on this subject, and about a hundred anti-angiogenic compounds entered in clinical trials, and numerous others in preclinical development [@b7]--[@b9]. Currently, it is well established that a deregulated and persistent angiogenesis is one of the hallmarks of cancer [@b10],[@b11]. Furthermore, there is overwhelming evidence on the involvement of deregulated angiogenesis in many other pathological situations, which are currently described as angiogenesis-dependent diseases [@b12]. The interest and impact of angiogenesis as a new therapeutical target from the treatment of non-oncological angiogenesis-dependent diseases is well represented by the recent concession of the Lasker-Debakey Clinical Medical Research Award 2010 to Dr. Napoleone Ferrara for the discovery of VEGF as a major mediator of angiogenesis and the development of an effective anti-VEGF therapy for wet macular degeneration, a leading cause of blindness in the elderly [@b13]. This is a type of age-related macular degeneration, included as a rare disease in the Orphanet website with the Orpha number ORPHA279. Other two examples of A-RDs are POEMS syndrome (ORPHA2905) [@b14],[@b15] and Amyotrophic lateral sclerosis (ORPHA803) [@b16].

In fact, a number of the so far described rare diseases are infrequent types of neoplasia, most probably related to angiogenesis. Furthermore, many other rare diseases could be related to angiogenesis. However, there is a lack of an exhaustive and systematic review on the topic "angiogenesis related rare diseases". To contribute to fill this gap is the main aim of the present review. To reach this goal, our group can make use or our previous experience in the management of databases and the implementation of bioinformatics tools [@b17]--[@b19]. As a research group integrated in the Spanish Network of Rare Disease Research (<http://www.ciberer.es/index.php?lang=english>), we are actively involved in the search of new sources of knowledge in this research area. In the present work, we aim to evaluate how much and what kind of information we are able to uncover in the context of A-RDs. Furthermore, we also evaluate what kind of information contained in Orphanet can be extracted within the frame of our systematic search.

Methods
=======

State of the art
----------------

The aim of this study was to perform a systematic study on the following question: *what scientific information can be drawn from those rare diseases that are related to the topic called angiogenesis?* To this end, we adapted the methodology stated in PRISMA statement (<http://www.prisma-statement.org/statement.htm>) for the systematic review of the whole set of documents that could be extracted from the databases used in this study [@b20],[@b21]. Table S1 in Supplementary material is the completed PRISMA checklist.

Strategy for the literature search
----------------------------------

### Eligibility criteria

*Types of studies*: This is a bibliometric study for the capture and identification of rare diseases appearing in different sources of scientific documentation and that are somehow related to angiogenesis.

*Report eligibility:* The scientific information specified in the previous section was exhaustively collected from scientific publications, namely, reviews, articles, case reports, proceedings and patents. The publication time ranged from 1991 to 2010 and there was no restriction concerning language or kind of publication. This search was dated in June of 2010 and updated in December of 2010. The whole set of collected rare diseases related to angiogenesis was submitted to a filter and selection procedure, according to their presence or not within a specialized database for rare diseases (Orphanet).

### Information sources

For the selection of scientific publications concerning rare diseases somehow related to angiogenesis, an online search of literature was carried out in both PubMed and ISI Web of Knowledge databases.

Search terms used were "rare disease" as a generic term and "angiogen\*". The use of the two terms "rare" and "disease" juxtaposed allowed to include any pathology with its name before the search term "disease" (*i.e*. Castleman disease, Von Willebrand disease, Wilson disease, Menkes disease, Crohn disease, among others) and made possible to associate the search term "rare" with other related semantic terms, such as in the cases of rare tumor, rare pathology or rare disorder, among others. Finally, the term "angiogen\*" was used as a root belonging to the generic term of angiogenesis and/or all possible variants.

As mentioned above, to validate the rare diseases found in this initial literature search, Orphanet database was used. Only those rare diseases contained and indexed within this database were confirmed and used for the rest of the study.

### Search

In PubMed database, search terms were introduced in *Advanced search* without time limit or any other limit and listed as "(rare disease) AND angiogen\*", according to the following structured search: "rare diseases"\[MeSH Terms\] OR ("rare"\[All Fields\] AND "diseases"\[All Fields\]) OR "rare diseases"\[All Fields\] OR ("rare"\[All Fields\] AND "disease"\[All Fields\]) OR "rare disease"\[All Fields\], along with more specific terms that appear by default in Medical Subject Heading (MeSH) hierarchical structure in Medline. MeSH categories were: Orphan Drug Production / All MeSH Categories / Diseases Category / Pathological Conditions, Signs and Symptoms / Pathologic Processes / Disease Attributes / Rare Diseases. The MeSH terms were: Disease, Rare / Diseases, Rare / Rare Disease / Orphan Diseases / Disease, Orphan / Diseases, Orphan / Orphan Disease.

Search terms were introduced in ISI Web of Knowledge database as topics in both cases. The annotated search structure was as follows: Topic=(rare disease) AND Topic=(angiogen\*). Timespan=All Years.

Study selection
---------------

### Bibliography selection

The two lists of publications mentioning one or several rare diseases somehow related to angiogenesis obtained by searching PubMed and ISI Web of Knowledge as described above were merged into a unique list containing all the entrances without repetition. In order to reduce the bias among the selected data and the data that really fit the list of search terms, all the information extracted was reviewed and verified. To reach this goal, all the publications contained in the merged list were revised one by one by making a strategic reading of them [@b22]. An analysis of matches was performed looking for the occurrence of the following terms "rare disease", and/or "rare", and/or "disease" and "angiogenic \*" or "VEGF" in all titles, abstracts, author keywords and keywords plus found and MeSH terms. All the references that did not support this exclusion analysis were removed.

### Rare diseases selection

Only those references containing explicit reference to one or more rare diseases (and therefore listed in Orphanet database with an Orpha identification number) were used to select those rare diseases included in the set to be further analyzed.

Data collection process and synthesis of indexed information
------------------------------------------------------------

### Data bibliographic systematic review

Once all the bibliographic information related to rare disease and angiogenesis was confirmed and validated, we proceeded to the analysis and compilation of all data of interest that Orphanet website could bring to the state of the art. All the collected data were allocated in sheets for the management of data in *Excel* format. This election was based on: (i) the easy access and operability of this format, (ii) the easy identification of data through the search option, and (iii) the capability to recover the original source of information through online links.

In a first column, the titles of all the selected bibliographic references in the study were included. The order or entrance was assigned according to publication dates, from the most recent to the oldest one.

All found and selected bibliographic references were categorized for each Orpha identification number validated with the applied selection criteria.

### Initial classification of angiogenesis-related rare diseases

A first general classification criterion was established according to which each disease was assigned to one of the three following disjoined subsets: A (A-RDs with cancerous phenotype in all their features), B (A-RDs with cancerous phenotype only in some of their features) and C (A-RDs without cancerous phenotype). To determine the three subsets, a systematic search of the semantic terms "tumor" and "cancer" and the sufix "-ome" was carried out within the classification that orpahanet exposes for rare diseases. The terms *glaucome, angiokeratome, lysosome, pseudoxanthome* and *hamartome* were excluded due to obvious reasons. After this, all corresponding genes and orphan drugs were seized from Orphanet database, categorized for each Orpha identification number and associated to A-RDs in different sheets.

### Bioinformatics analysis of bibliographic systematic review

To validate our manual systematic review of literature, we carried out an additional bioinformatics text mining study. The list of PubMed IDs (PMIDs) was obtained from the initial systematic review (all references of supplementary material, with the exception of references 5, 41, 44, 63 and 71) and uploaded into the text mining web application SciMiner [@b23]. A biomedical literature mining analysis and the subsequent enrichment analysis were carried out concerning to those Medical Subject Headings (MeSH) associated with the retrieved PMIDs from the systematic review.

Results of the literature search and orphanet analysis
======================================================

Bibliographic systematic review
-------------------------------

As shown in the scheme depicted in Figure[1](#fig01){ref-type="fig"}, the search in ISI Web of Knowledge yielded 284 references, whereas that carried out in PubMed yielded 263 references. From all these references, only 187 fulfilled the selection criteria for their inclusion in the set to be further analyzed. The complete set of the 187 selected bibliographic references conforms the bibliography included in the Supplementary material and they validate the entrance of 180 A-RDs indexed in the database Orphanet (see Methods). An evaluation of this bibliographic set using PMIDs was carried out as described (see Methods). To avoid the occurrence of trivial MeSH terms, we have considered statistically significant only those terms with a *P*-value lower than 1.0E-5 and an enrichment (t-ratio/b-ratio) greater than 40. The results are shown in Table[1](#tbl1){ref-type="table"}. Figure S1 (Supplementary material) shows the PRISMA flow diagram corresponding to this systematic review.

![Flow of information through the different phases of bibliographic systematic review.](jcmm0016-2872-f1){#fig01}

###### 

Bioinformatic analysis of bibliographic systematic review

  MeSH                                            t+   t−    b+       b−           WholeSize    t-Ratio   b-Ratio    t-ratio/b-ratio   *P*-value
  ----------------------------------------------- ---- ----- -------- ------------ ------------ --------- ---------- ----------------- -----------
  Angiogenesis inhibitors                         33   149   8120     19,435,023   19,443,143   0.18      4.18E-04   434.2             6.18E-76
  Neovascularization, pathologic                  31   151   22,709   19,420,434   19,443,143   0.17      1.17E-03   145.8             9.89E-57
  Vascular endothelial growth factor A            18   164   20,847   19,422,296   19,443,143   0.1       1.07E-03   92.2              9.41E-30
  Thalidomide                                     12   170   4628     19,438,515   19,443,143   0.07      2.38E-04   277               6.17E-26
  Herpesvirus 8, human                            9    173   3009     19,440,134   19,443,143   0.05      1.55E-04   319.5             2.49E-20
  Macular degeneration                            7    175   7925     19,435,218   19,443,143   0.04      4.08E-04   94.4              2.06E-12
  von Hippel--Lindau disease                      5    177   1744     19,441,399   19,443,143   0.03      8.97E-05   306.3             9.10E-12
  Lymphangioleiomyomatosis                        4    178   569      19,442,574   19,443,143   0.02      2.93E-05   751               3.29E-11
  Endothelial cells                               7    175   15,420   19,427,723   19,443,143   0.04      7.93E-04   48.5              2.05E-10
  Carcinoma, renal cell                           7    175   16,035   19,427,108   19,443,143   0.04      8.25E-04   46.6              2.68E-10
  Exudates and transudates                        6    176   8354     19,434,789   19,443,143   0.03      4.30E-04   76.7              2.75E-10
  Hypoxia-inducible factor 1, alpha subunit       5    177   4123     19,439,020   19,443,143   0.03      2.12E-04   129.6             6.57E-10
  Vascular malformations                          3    179   311      19,442,832   19,443,143   0.02      1.60E-05   1030.5            4.11E-09
  Telangiectasia, hereditary hemorrhagic          4    178   1929     19,441,214   19,443,143   0.02      9.92E-05   221.5             4.25E-09
  Activin receptors, type II                      3    179   346      19,442,797   19,443,143   0.02      1.78E-05   926.3             5.65E-09
  Hemangioendothelioma, epithelioid               3    179   459      19,442,684   19,443,143   0.02      2.36E-05   698.2             1.31E-08
  Vascular endothelial growth factors             5    177   7692     19,435,451   19,443,143   0.03      3.96E-04   69.4              1.44E-08
  Angiogenic proteins                             3    179   482      19,442,661   19,443,143   0.02      2.48E-05   664.9             1.52E-08
  POEMS syndrome                                  3    179   486      19,442,657   19,443,143   0.02      2.50E-05   659.4             1.56E-08
  Osteolysis, essential                           3    179   541      19,442,602   19,443,143   0.02      2.78E-05   592.4             2.15E-08
  Hemangioma, capillary                           3    179   665      19,442,478   19,443,143   0.02      3.42E-05   481.9             3.97E-08
  Protein kinase inhibitors                       5    177   10,840   19,432,303   19,443,143   0.03      5.58E-04   49.3              7.82E-08
  Interferon-alpha                                5    177   11637    19,431,506   19,443,143   0.03      5.99E-04   45.9              1.11E-07
  Pyrroles                                        5    177   11,893   19,431,250   19,443,143   0.03      6.12E-04   44.9              1.23E-07
  Von Hippel--Lindau tumor suppressor protein     3    179   1082     19,442,061   19,443,143   0.02      5.56E-05   296.2             1.70E-07
  Hypoxia-inducible factor 1                      3    179   1746     19,441,397   19,443,143   0.02      8.98E-05   183.6             7.10E-07
  Endothelial growth factors                      4    178   7866     19,435,277   19,443,143   0.02      4.05E-04   54.3              1.12E-06
  Sarcoma, kaposi                                 4    178   8163     19,434,980   19,443,143   0.02      4.20E-04   52.3              1.30E-06
  Linkage disequilibrium                          4    178   8690     19,434,453   19,443,143   0.02      4.47E-04   49.2              1.66E-06
  Rare diseases                                   3    179   2370     19,440,773   19,443,143   0.02      1.22E-04   135.2             1.77E-06
  Collagen type XVIII                             2    180   202      19,442,941   19,443,143   0.01      1.04E-05   1057.7            1.80E-06
  Receptors, vascular endothelial growth factor   3    179   2497     19,440,646   19,443,143   0.02      1.28E-04   128.4             2.06E-06
  Lipoid proteinosis of urbach and wiethe         2    180   246      19,442,897   19,443,143   0.01      1.27E-05   868.5             2.67E-06
  Retinal vessels                                 4    178   9999     19,433,144   19,443,143   0.02      5.14E-04   42.7              2.88E-06
  Stem cell transplantation                       4    178   10,093   19,433,050   19,443,143   0.02      5.19E-04   42.3              2.99E-06
  Receptors, CXCR4                                3    179   3315     19,439,828   19,443,143   0.02      1.70E-04   96.7              4.80E-06
  Dacarbazine                                     3    179   3542     19,439,601   19,443,143   0.02      1.82E-04   90.5              5.84E-06

MeSH, medical subject headings; t+, number of papers annotated with the MeSH in the sample PMIDs; t−, number of papers not annotated with the MeSH in the sample PMIDs; b+, number of papers annotated with the MeSH in whole PMIDs; b−, number of papers not annotated with the MeSH in whole PMIDs; WholeSize, whole PMIDs; t-ratio, proportion in the sample PMIDs; b-ratio, proportion in the whole PMIDs; t-ratio/b-ratio, value relative to the enrichment of the MeSH term; and *P*-value, Hypergeometric test value.

Initial classification of angiogenesis-related rare diseases
------------------------------------------------------------

When this analysis was carried out, the Orphanet web contained 5781 rare diseases. This means that a 3% of all the described rare diseases can be considered as A-RDs.

In the present work, the distribution of A-RDs within the subsets A, B, C as a function of the classification range pointed by Orphanet (for those which have a classification in this database) was analyzed. This initial classification was based on the tight physio-pathological relationship of cancer with angiogenesis [@b4]--[@b9], their relevant clinical and pharmacological applications [@b7]--[@b9] and the bibliographic relevance of the Boolean descriptor "cancer AND angiogenesis". As expected, the greatest subset is that of rare oncologic diseases (subset A), which amounted up to 81 A-RDs. However, the subset C (A-RDs without cancerous phenotype) was almost as big, containing 76 non-oncologic A-RDs. Finally, the subset B (A-RDs with cancerous phenotype only in some of their features) contained 23 diseases, most of them increasing the risk of developing a cancer. Table[2](#tbl2){ref-type="table"} show the lists of A-RDs in each of the three subsets, their relationship with bibliographic references of the supplementary material and the number of genes and drugs associated to each A-RD.

###### 

Angiogenesis-related rare diseases

  *n°*                                                                       References                                                            Orpha ID   Rare disease                                                                                        Orpha genes   Orpha drugs
  -------------------------------------------------------------------------- --------------------------------------------------------------------- ---------- --------------------------------------------------------------------------------------------------- ------------- -------------
  Subset A (rare oncologic diseases)                                                                                                                                                                                                                                            
  1                                                                          \[[@b1], 136\]                                                        519        Acute myeloid leukemia (ARD)[\*](#tf2-1){ref-type="table-fn"}                                       19            33
  2                                                                          \[59\]                                                                213772     Adenocarcinoma of the cervix uteri                                                                  0             0
  3                                                                          \[128\]                                                               1501       Adrenocortical carcinoma                                                                            0             1
  4                                                                          \[47\]                                                                163699     Alveolar soft-part sarcoma                                                                          2             0
  5                                                                          \[114\]                                                               142        Anaplastic thyroid carcinoma                                                                        0             1
  6                                                                          \[52\]                                                                86886      Angioimmunoblastic T-cell lymphoma                                                                  0             0
  7                                                                          [@b11]                                                                98731      Arteriovenous fistula                                                                               0             0
  8                                                                          \[23, 26, 68, 79, 105, 143\]                                          211266     Arteriovenous malformation                                                                          0             0
  9                                                                          \[51\]                                                                157980     Bladder Cancer                                                                                      0             0
  10                                                                         \[125, 134\]                                                          223727     Bone sarcoma                                                                                        7             0
  11                                                                         \[83\]                                                                3395       Brain tumor (ARD)[\*](#tf2-1){ref-type="table-fn"}                                                  17            0
  12                                                                         \[165\]                                                               97287      Bronchial endocrine tumor                                                                           0             0
  13                                                                         \[26\]                                                                137667     Capillary malformation-arteriovenous malformation                                                   1             0
  14                                                                         \[45, 112, 143, 152\]                                                 164        Cerebral cavernous malformations                                                                    0             0
  15                                                                         \[99\]                                                                86829      Chronic neutrophilic leukemia                                                                       0             0
  16                                                                         \[61\]                                                                99970      Dedifferentiated liposarcoma                                                                        0             0
  17                                                                         \[61\]                                                                31112      Dermatofibrosarcoma protuberans                                                                     2             0
  18                                                                         [@b15]                                                                141209     Diffuse lymphatic malformation                                                                      0             0
  19                                                                         \[29, 138, 167\]                                                      877        Endocrine tumor                                                                                     2             2
  20                                                                         \[29\]                                                                100092     Enteropancreatic endocrine tumor                                                                    0             2
  21                                                                         \[103\]                                                               99871      Eosinophilic granuloma                                                                              0             0
  22                                                                         \[65, 98, 139, 162\]                                                  157791     Epithelioid hemangioendothelioma                                                                    0             0
  23                                                                         \[147, 149\]                                                          99976      Esophageal adenocarcinoma                                                                           0             0
  24                                                                         \[149\]                                                               99977      Esophageal squamous cell carcinoma                                                                  1             0
  25                                                                         \[61, 134\]                                                           319        Ewing sarcoma                                                                                       5             0
  26                                                                         \[51, 146, 164\]                                                      733        Familial adenomatous polyposis                                                                      1             4
  27                                                                         \[64\]                                                                523        Familial leiomyomatosis                                                                             1             0
  28                                                                         [@b20]                                                                99361      Familial medullary thyroid carcinoma                                                                0             0
  29                                                                         \[39, 42, 47, 92, 104, 159, 160\]                                     151        Familial renal cell carcinoma (ARD)[\*](#tf2-1){ref-type="table-fn"}                                11            22
  30                                                                         \[70, 135\]                                                           63443      Gastric cancer                                                                                      2             5
  31                                                                         \[61, 97\]                                                            44890      Gastrointestinal stromal tumor                                                                      2             5
  32                                                                         \[[@b5], 36, 83\]                                                     360        Glioblastoma                                                                                        8             33
  33                                                                         \[[@b5], 83\]                                                         182067     Glial tumor (ARD)[\*](#tf2-1){ref-type="table-fn"}                                                  9             26
  34                                                                         \[45\]                                                                83454      Glomuvenous malformation                                                                            1             1
  35                                                                         \[34\]                                                                99915      Granulosa cell malignant tumor                                                                      0             0
  36                                                                         \[184\]                                                               58017      Hairy cell leukemia                                                                                 0             2
  37                                                                         \[76\]                                                                2126       Hemangiopericytoma                                                                                  0             0
  38                                                                         \[123, 137\]                                                          88673      Hepatocellular carcinoma (ARD)[\*](#tf2-1){ref-type="table-fn"}                                     2             14
  39                                                                         \[141\]                                                               227535     Hereditary breast cancer                                                                            0             0
  40                                                                         \[94, 107\]                                                           29072      Hereditary pheochromocytoma-paraganglioma syndrome                                                  6             0
  41                                                                         \[166, 167\]                                                          97279      Insulinoma                                                                                          0             3
  42                                                                         \[87, 118, 144, 158, 162, 169, 172, 177, 179, 180, 181, 185, 186\]    33276      Kaposi\'s sarcoma                                                                                   0             5
  43                                                                         [@b22]                                                                213807     Leiomyosarcoma of the cervix uteri                                                                  0             0
  44                                                                         [@b22]                                                                213625     Leiomyosarcoma of the corpus uteri                                                                  0             0
  45                                                                         \[111\]                                                               65285      Lhermitte-Duclos disease (ARD)[\*](#tf2-1){ref-type="table-fn"}                                     1             0
  46                                                                         \[141\]                                                               524        Li-Fraumeni syndrome                                                                                2             1
  47                                                                         \[173\]                                                               69078      Liposarcoma                                                                                         1             2
  48                                                                         \[[@b24], 75\]                                                        168811     Malignant peritoneal mesothelioma                                                                   0             0
  49                                                                         \[67, 112\]                                                           3148       Malignant Schwannoma                                                                                0             0
  50                                                                         [@b6]                                                                 98292      Mastocytosis                                                                                        1             1
  51                                                                         \[[@b20], 165\]                                                       1332       Medullary thyroid carcinoma                                                                         1             3
  52                                                                         \[56\]                                                                97338      Melanoma of soft part                                                                               2             0
  53                                                                         \[[@b24], 75\]                                                        50251      Mesothelioma                                                                                        0             3
  54                                                                         \[55, 77, 140, 166, 178, 184\]                                        29073      Multiple myeloma                                                                                    2             23
  55                                                                         [@b1]                                                                 52688      Myelodysplastic syndromes                                                                           2             10
  56                                                                         \[61\]                                                                99967      Myxoid liposarcoma                                                                                  1             0
  57                                                                         \[80\]                                                                209989     Non-papillary transitional cell carcinoma of the bladder                                            0             1
  58                                                                         \[134\]                                                               668        Osteosarcoma                                                                                        2             5
  59                                                                         \[59\]                                                                213504     Ovarian adenocarcinoma                                                                              0             7
  60                                                                         \[142\]                                                               2800       Paget disease extramammary                                                                          0             0
  61                                                                         \[165\]                                                               217074     Pancreatic carcinoma                                                                                7             21
  62                                                                         \[94\]                                                                717        Pheochromocytoma and secreting paraganglioma (ARD)[\*](#tf2-1){ref-type="table-fn"}                 8             1
  63                                                                         \[[@b14], 66, 115\]                                                   2905       POEMS syndrome                                                                                      0             0
  64                                                                         \[87, 169, 172, 177, 180\]                                            48686      Primary effusion lymphoma                                                                           0             0
  65                                                                         \[87, 144, 169, 172, 180, 181\]                                       99923      Primary effusion lymphoma associated with HIV infection                                             0             0
  66                                                                         \[59\]                                                                213528     Rare adenocarcinoma of the breast                                                                   0             0
  67                                                                         \[74\]                                                                180250     Rare breast cancer (ARD)[\*](#tf2-1){ref-type="table-fn"}                                           12            0
  68                                                                         \[[@b12], 28, 39, 42, 47, 57, 63, 84, 92, 104, 122, 159, 160, 182\]   217071     Renal cell carcinoma (ARD)[\*](#tf2-1){ref-type="table-fn"}                                         12            24
  69                                                                         \[61\]                                                                69077      Rhabdoid tumor                                                                                      2             0
  70                                                                         \[165\]                                                               70573      Small cell lung cancer                                                                              0             4
  71                                                                         \[[@b9], 22, 56, 97, 125, 173\]                                       3394       Soft tissue sarcomas                                                                                20            10
  72                                                                         \[162\]                                                               210584     Spindle cell hemangioma                                                                             0             0
  73                                                                         \[93\]                                                                67037      Squamous cell carcinoma of head and neck (ARD)[\*](#tf2-1){ref-type="table-fn"}                     4             5
  74                                                                         \[131\]                                                               99868      Thymic carcinoma                                                                                    0             0
  75                                                                         \[131\]                                                               3398       Thymic epithelial tumor                                                                             0             0
  76                                                                         \[131\]                                                               100100     Thymic tumor                                                                                        0             0
  77                                                                         \[131\]                                                               99867      Thymoma                                                                                             0             0
  78                                                                         \[133\]                                                               1063       Tufted angioma                                                                                      0             0
  79                                                                         \[52\]                                                                86885      Unspecified peripheral T-cell lymphoma                                                              0             4
  80                                                                         \[85, 88, 159\]                                                       39044      Uveal melanoma                                                                                      0             1
  81                                                                         \[61\]                                                                99971      Well-differentiated liposarcoma                                                                     0             0
  Subset B (A-RDs with cancerous phenotype only in some of their features)                                                                                                                                                                                                      
  1                                                                          \[111\]                                                               109        Bannayan-Riley-Ruvalcaba syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                            1             0
  2                                                                          \[89, 184\]                                                           521        Chronic myeloid leukemia (ARD)[\*](#tf2-1){ref-type="table-fn"}                                     3             12
  3                                                                          \[69\]                                                                53721      Cobb syndrome                                                                                       0             0
  4                                                                          \[60, 109\]                                                           191        Cockayne syndrome                                                                                   5             0
  5                                                                          \[95\]                                                                2414       Congenital pulmonary lymphangiectasia                                                               0             0
  6                                                                          \[111\]                                                               201        Cowden syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                                              3             0
  7                                                                          [@b17]                                                                324        Fabry disease                                                                                       1             3
  8                                                                          \[[@b15],[@b16], 73, 118\]                                            73         Gorham-Stout disease                                                                                0             0
  9                                                                          \[35, 110\]                                                           90308      Klippel-Trenaunay syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                                   1             0
  10                                                                         \[90\]                                                                389        Langerhans cell histiocytosis                                                                       0             1
  11                                                                         \[174\]                                                               79383      Lymphedema (ARD)[\*](#tf2-1){ref-type="table-fn"}                                                   4             0
  12                                                                         \[50\]                                                                2451       Mucocutaneous venous malformations (ARD)[\*](#tf2-1){ref-type="table-fn"}                           1             1
  13                                                                         \[166, 167\]                                                          652        Multiple endocrine neoplasia type 1                                                                 2             2
  14                                                                         \[89, 148\]                                                           824        Myelofibrosis with myeloid metaplasia                                                               1             2
  15                                                                         \[[@b2], 61\]                                                         636        Neurofibromatosis type 1 (ARD)[\*](#tf2-1){ref-type="table-fn"}                                     3             2
  16                                                                         \[53\]                                                                2869       Peutz-Jeghers syndrome                                                                              1             0
  17                                                                         \[91\]                                                                42775      PHACE syndrome                                                                                      0             0
  18                                                                         \[89\]                                                                729        Polycythemia vera                                                                                   1             5
  19                                                                         \[174\]                                                               77240      Primary lymphedema                                                                                  2             0
  20                                                                         \[[@b8],[@b13],[@b23], 45, 79, 105, 143\]                             774        Rendu-Osler-Weber disease (ARD)[\*](#tf2-1){ref-type="table-fn"}                                    3             1
  21                                                                         \[37, 88\]                                                            3205       Sturge-Weber syndrome                                                                               0             0
  22                                                                         \[[@b12], 29, 39, 42, 84, 88, 92, 122, 130, 161, 170, 182\]           892        Von Hippel--Lindau disease (ARD)[\*](#tf2-1){ref-type="table-fn"}                                   1             2
  23                                                                         \[187\]                                                               913        Zollinger-Ellison syndrome                                                                          1             3
  Subset C (A-RDs without cancerous phenotype)                                                                                                                                                                                                                                  
  1                                                                          \[25\]                                                                93585      Acquired thrombotic thrombocytopenic purpura due to anti-ADAMTS 13 antibodies                       0             1
  2                                                                          \[54\]                                                                79126      Acute interstitial pneumonia                                                                        0             0
  3                                                                          \[[@b19], 27, 32, 40, 43, 48, 62, 88, 176\]                           279        Age-related macular degeneration                                                                    6             1
  4                                                                          \[58, 126\]                                                           803        Amyotrophic lateral sclerosis (ARD)[\*](#tf2-1){ref-type="table-fn"}                                17            10
  5                                                                          \[35, 110\]                                                           2346       Angio-osteohypertrophic syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                             2             0
  6                                                                          \[25\]                                                                2134       Atypical hemolytic uremic syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                           6             3
  7                                                                          \[154\]                                                               3453       Autoimmune polyendocrinopathy type 1                                                                1             0
  8                                                                          \[46\]                                                                117        Behcet disease                                                                                      0             2
  9                                                                          [@b21]                                                                131        Budd-Chiari syndrome                                                                                0             0
  10                                                                         \[30, 120\]                                                           36258      Buerger\'s disease                                                                                  0             0
  11                                                                         \[152\]                                                               136        CADASIL syndrome                                                                                    1             0
  12                                                                         \[31, 179, 185\]                                                      160        Castleman disease                                                                                   0             2
  13                                                                         \[154\]                                                               178029     Central diabetes insipidus                                                                          1             0
  14                                                                         \[68\]                                                                98044      Central nervous system malformation                                                                 0             0
  15                                                                         \[40\]                                                                179        Chorioretinopathy, Birdshot type                                                                    1             0
  16                                                                         \[155\]                                                               2137       Chronic autoimmune hepatitis                                                                        0             1
  17                                                                         \[117\]                                                               183        Churg-Strauss syndrome                                                                              0             1
  18                                                                         \[40, 109\]                                                           190        Coats disease                                                                                       1             0
  19                                                                         \[78\]                                                                2041       Coronary arterial fistulas                                                                          0             0
  20                                                                         \[[@b6], 103, 133\]                                                   206        Crohn disease                                                                                       5             0
  21                                                                         \[116\]                                                               137698     Cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk             0             1
  22                                                                         \[68\]                                                                97339      Dural sinus malformation                                                                            0             0
  23                                                                         \[40\]                                                                40923      Eales disease                                                                                       0             0
  24                                                                         \[165\]                                                               99889      Ectopic Cushing syndrome                                                                            0             1
  25                                                                         \[72\]                                                                199323     Endophthalmitis                                                                                     0             0
  26                                                                         \[183\]                                                               337        Fibrodysplasia ossificans progressiva (ARD)[\*](#tf2-1){ref-type="table-fn"}                        1             0
  27                                                                         \[45\]                                                                2092       Focal dermal hypoplasia                                                                             1             0
  28                                                                         [@b3]                                                                 221126     Fowler syndrome                                                                                     1             0
  29                                                                         [@b17]                                                                355        Gaucher disease                                                                                     2             5
  30                                                                         [@b17]                                                                77260      Gaucher disease, type 2                                                                             1             4
  31                                                                         [@b17]                                                                77261      Gaucher disease, type 3                                                                             1             4
  32                                                                         \[154\]                                                               95509      Granulomatous hypophysitis                                                                          0             0
  33                                                                         \[121\]                                                               855        Hashimoto struma                                                                                    1             0
  34                                                                         \[90\]                                                                158032     Hemophagocytic syndrome                                                                             14            1
  35                                                                         \[132, 152\]                                                          85458      Hereditary cerebral hemorrhage with amyloidosis                                                     2             0
  36                                                                         \[132\]                                                               100006     Hereditary cerebral hemorrhage with amyloidosis, Dutch type                                         0             0
  37                                                                         \[157\]                                                               422        Idiopathic and/or familial pulmonary arterial hypertension (ARD)[\*](#tf2-1){ref-type="table-fn"}   3             17
  38                                                                         [@b21]                                                                69665      Intrahepatic cholestasis of pregnancy                                                               2             0
  39                                                                         \[100\]                                                               2778       Juvenile chronic recurrent multifocal osteomyelitis                                                 0             0
  40                                                                         \[82\]                                                                2331       Kawasaki disease                                                                                    0             1
  41                                                                         \[156\]                                                               1571       Knobloch syndrome (ARD)[\*](#tf2-1){ref-type="table-fn"}                                            1             0
  42                                                                         \[101, 163\]                                                          530        Lipoid proteinosis (ARD)[\*](#tf2-1){ref-type="table-fn"}                                           1             0
  43                                                                         \[[@b7], 108\]                                                        538        Lymphangioleiomyomatosis                                                                            2             0
  44                                                                         [@b17]                                                                93448      Lysosomal storage disease with skeletal involvement                                                 22            0
  45                                                                         \[86\]                                                                101338     Mediterranean spotted fever                                                                         0             0
  46                                                                         \[168\]                                                               54370      Membranoproliferative glomerulonephritis                                                            1             0
  47                                                                         \[10, 127, 145\]                                                      565        Menkes disease                                                                                      1             0
  48                                                                         \[68, 106\]                                                           2573       Moyamoya disease                                                                                    1             0
  49                                                                         \[87, 144, 169, 172, 177, 180\]                                       93686      Multicentric Castleman disease                                                                      0             0
  50                                                                         \[176\]                                                               94058      Neovascular glaucoma                                                                                1             0
  51                                                                         \[129\]                                                               649        Norrie disease                                                                                      1             0
  52                                                                         \[25\]                                                                447        Paroxysmal nocturnal hemoglobinuria                                                                 0             2
  53                                                                         [@b17]                                                                85212      Perinatal-lethal Gaucher disease                                                                    1             0
  54                                                                         [@b18]                                                                563        Peripartum cardiomyopathy                                                                           0             0
  55                                                                         \[40\]                                                                758        Pseudoxanthoma elasticum                                                                            1             0
  56                                                                         \[[@b4], 113, 157\]                                                   182090     Pulmonary arterial hypertension                                                                     0             3
  57                                                                         \[96, 153\]                                                           199241     Pulmonary capillary hemangiomatosis                                                                 0             2
  58                                                                         \[113\]                                                               71198      Rare pulmonary hypertension                                                                         0             1
  59                                                                         \[38\]                                                                60032      Recurrent respiratory papillomatosis                                                                0             0
  60                                                                         \[40, 102, 171, 176\]                                                 90050      Retinopathy of prematurity                                                                          1             2
  61                                                                         \[33\]                                                                49041      Retroperitoneal fibrosis                                                                            0             0
  62                                                                         \[86\]                                                                102021     Rickettsiae disease                                                                                 0             0
  63                                                                         \[[@b17], 82\]                                                        797        Sarcoidosis                                                                                         1             2
  64                                                                         \[81, 124\]                                                           801        Scleroderma                                                                                         0             3
  65                                                                         \[166\]                                                               36426      Stevens-Johnson syndrome                                                                            0             0
  66                                                                         \[99\]                                                                3243       Sweet syndrome                                                                                      0             0
  67                                                                         \[116, 119, 154\]                                                     536        Systemic lupus erythematosus                                                                        2             1
  68                                                                         \[81\]                                                                90291      Systemic sclerosis                                                                                  0             3
  69                                                                         \[135\]                                                               93573      Thrombotic microangiopathy                                                                          0             0
  70                                                                         \[25, 151\]                                                           54057      Thrombotic thrombocytopenic purpura                                                                 1             5
  71                                                                         \[25\]                                                                90038      Typical hemolytic uremic syndrome                                                                   0             1
  72                                                                         \[117\]                                                               52759      Vasculitis                                                                                          0             0
  73                                                                         \[49, 109, 129\]                                                      98668      Vitreoretinopathy (ARD)[\*](#tf2-1){ref-type="table-fn"}                                            14            0
  74                                                                         \[86, 151, 175\]                                                      903        Von Willebrand disease                                                                              1             3
  75                                                                         \[150\]                                                               51636      WHIM syndrome                                                                                       1             0
  76                                                                         \[82, 127, 145\]                                                      905        Wilson disease                                                                                      1             4

ARD: angiogenic rare disease.

Since Orphanet identifies genes listed in its database such as those considered to be involved in the pathophysiology of rare diseases and because this information is extracted from the scientific literature and cross-validated, genes directly related to angiogenesis and A-RDs can be associated (*i.e*. those genes linked to A-RDs in the systematic review and in the same way recovered with the Gene Ontology GO term called angiogenesis; GO:0001525). In this context, we consider that diseases recovered in this way can be called "angiogenic rare diseases" and they can be retrieved from those 180 rare diseases related in some way with angiogenesis. These 27 angiogenic rare diseases are also highlighted in Table[2](#tbl2){ref-type="table"}.

The most commonly used classification of diseases is WHO ICD-10 (<http://www.who.int/classifications/icd/en>). Tables S2--S4 (Supplementary material) list A-RDs corresponding to subsets A, B, and C, respectively, indicating their ICD-10 when available. It is noteworthy that as many as 83 A-RDs (47 in subset A, 6 in subset B and 30 in subset C) have currently no ICD code assigned.

Genes and drugs associated to angiogenesis-related rare diseases
----------------------------------------------------------------

We manually collected 244 entrances identified as genes in Orphanet. To study the relative distribution of the set of extracted and annotated genes in the list of A-RDs, and also to know their representation in the three initial subsets (A, B, C), three categories of A-RDs where established: those currently associated to no gene, those associated to one gene, and those with two or more genes associated. The number of genes in each A-RD is highlighted in Table[2](#tbl2){ref-type="table"}. Furthermore, Tables S5 and S6 (Supplementary material) list all the A-RDs associated to a single or to more than a gene, respectively, identifying the corresponding related genes by their Orpha gene IDs.

It is interesting to note that this relationship among genes and A-RDs is not symmetrical. Tables[3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"} list the whole set of 186 genes associated to one A-RD and 58 genes associated to two or more A-RDs, respectively, identifying the corresponding A-RDs by their Orpha rare disease IDs. Figure[2](#fig02){ref-type="fig"} shows the distribution of the annotated genes grouped in two categories (those associated to one A-RD and those associated to two or more A-RDs in the whole set and the three subsets of A-RDs.

![Relative distribution of genes associated to angiogenesis-related rare disease. Percentages of genes belonging to described subsets of A-RDs: A (A-RDs with cancerous phenotype in all their features), B (A-RDs with cancerous phenotype only in some of their features) and C (A-RDs without cancerous phenotype). Horizontal-axis represents the distribution of genes in the different subsets. Color code: blue, genes related to one A-RD; brownish, genes related to two or more A-RDs; dark grey: total genes related to A-RDs.](jcmm0016-2872-f2){#fig02}

###### 

Genes associated to a single angiogenesis-related rare disease

  *n*′   Genes                               Rare disases Orpha ID
  ------ ----------------------------------- -----------------------
  1      *ACTA2*                             2573 (C)
  2      *ATF1*                              97338 (A)
  3      *ACVR1*                             337 (C)
  4      *ADAMTS13*                          54057 (C)
  5      *AP3B1*                             158032 (C)
  6      *ARMS2*                             279 (C)
  7      *APP*                               85458 (C)
  8      *ALS2*                              803 (C)
  9      *ALK*                               3395 (A)
  10     *ANG*                               803 (C)
  11     *(TATCCGGAGGGCTCGCCATGCTGCT)*       94058 (C)
  12     *AVP*                               178029 (C)
  13     *ARSB*                              93448 (C)
  14     *AGA*                               93448 (C)
  15     *ATG16L1*                           206 (C)
  16     *ATP8B1*                            69665 (C)
  17     *ATP7A*                             565 (C)
  18     *ATP7B*                             905 (C)
  19     *ABCA4*                             279 (C)
  20     *ABCB4*                             69665 (C)
  21     *ABCC6*                             758 (C)
  22     *AIRE*                              3453 (C)
  23     *BEST1*                             98668 (C)
  24     *BLOC1S3*                           158032 (C)
  25     *BMPR2*                             422 (C)
  26     *BARD1*                             180250 (A)
  27     *BRIP1*                             180250 (A)
  28     *BCR*                               521 (B)
  29     *BRCA1*                             180250 (A)
  30     *CDH1*                              63443 (A)
  31     *CREB3L1*                           3394 (A)
  32     *CREB3L2*                           3394 (A)
  33     *Cathepsin A---CTSA*                93448 (C)
  34     *CEBPA*                             519 (A)
  35     *CD46*                              2134 (C)
  36     *CXCR4*                             51636 (C)
  37     *CHGB*                              803 (C)
  38     *COL2A1*                            98668 (C)
  39     *COL9A1*                            98668 (C)
  40     *COL11A1*                           98668 (C)
  41     *COL11A2*                           98668 (C)
  42     *CR1*                               536 (C)
  43     *C3*                                2134 (C)
  44     *CFB*                               2134 (C)
  45     *CFI*                               2134 (C)
  46     *CBFB*                              519 (A)
  47     *CDKN1B*                            652 (B)
  48     *CDKN2A*                            217074 (A)
  49     *CST3*                              85458 (C)
  50     *CTLA4*                             536 (C)
  51     *DAO*                               803 (C)
  52     *DEK*                               519 (A)
  53     *DTNBP1*                            158032 (C)
  54     *ENG*                               774 (B)
  55     *ETV6*                              519 (A)
  56     *ERCC1*                             191 (B)
  57     *ERCC2*                             191 (B)
  58     *ERCC5*                             191 (B)
  59     *ERCC6*                             191 (B)
  60     *ERCC8*                             191 (B)
  61     *EXT1*                              223727 (A)
  62     *ECM1*                              530 (C)
  63     *FCGR3B*                            855 (C)
  64     *FLVCR2*                            2211 (C)
  65     *FBLN5*                             279 ((C)
  66     *FIG* [4](#fig04){ref-type="fig"}   803 (C)
  67     *FLT3*                              519 (A)
  68     *FOXC2*                             79383 (B)
  69     *FOXO1*                             3394 (A)
  70     *FZD4*                              98668 (C)
  71     *FUCA1*                             93448 (C)
  72     *GALNS*                             93448 (C)
  73     *GLA*                               324 (B)
  74     *GLB1*                              93448 (C)
  75     *GLMN*                              83454 (A)
  76     *GNS*                               93448 (C)
  77     *GUSB*                              93448 (C)
  78     *HMCN1*                             279 (C)
  79     *HGSNAT*                            93448 (C)
  80     *HPS1*                              158032 (C)
  81     *HPS3*                              158032 (C)
  82     *HPS4*                              158032 (C)
  83     *HPS5*                              158032 (C)
  84     *HPS6*                              158032 (C)
  85     *HTRA1*                             279 (C)
  86     *HYAL1*                             93448 (C)
  87     *IDS*                               93448 (C)
  88     *IDUA*                              93448 (C)
  89     *IGHG1*                             29073 (A)
  90     *ING1*                              67037 (A)
  91     *ING3*                              67037 (A)
  92     *INSM1*                             877 (A)
  93     *IRF4*                              29073 (A)
  94     *IL10*                              206 (C)
  95     *IL23R*                             206 (C)
  96     *LRP5*                              98668 (C)
  97     *LYST*                              158032 (C)
  98     *HLA-A*                             179 (C)
  99     *HLA-DRB1*                          797 (C)
  100    *MAN2B1*                            93448 (C)
  101    *MANBA*                             93448 (C)
  102    *MECOM*                             52688 (A)
  103    *MKL1*                              519 (A)
  104    *MANF*                              217074 (A)
  105    *MUTYH*                             63443 (A)
  106    *MLL*                               519 (A)
  107    *MYH11*                             519 (A)
  108    *MYST3*                             519 (A)
  109    *GNPTAB*                            93448 (C)
  110    *GNPTG*                             93448 (C)
  111    *NAGLU*                             93448 (C)
  112    *NF1*                               636 (B)
  113    *NEFH*                              803 (C)
  114    *NME1*                              3395 (A)
  115    *SGSH*                              93448 (C)
  116    *NR1H3*                             803 (C)
  117    *NR2E3*                             98668 (C)
  118    *NPM1*                              519 (A)
  119    *NUP214*                            519 (A)
  120    *NUP98*                             519 (A)
  121    *NOD2*                              206 (C)
  122    *OPTN*                              803 (C)
  123    *PAX3*                              3394 (A)
  124    *PAX7*                              3394 (A)
  125    *PHOX2B*                            3395 (A)
  126    *PON1*                              803 (C)
  127    *PON2*                              803 (C)
  128    *PON3*                              803 (C)
  129    *PTCH2*                             3395 (A)
  130    *PRF1*                              158032 (C)
  131    *PRPH*                              803 (C)
  132    *PLCE1*                             99977 (A)
  133    *PDGFRA*                            44890
  134    *PORCN*                             2092 (C)
  135    *KCNJ13*                            98668 (C)
  136    *PRLR*                              180250 (A)
  137    *PML*                               519 (A)
  138    *PSAP*                              355 (C)
  139    *RAB27A*                            158032 (C)
  140    *RAD51*                             180250 (A)
  141    *RAD51C*                            180250 (A)
  142    *RB1*                               668 (A)
  143    *RARA*                              519 (A)
  144    *RS1*                               98668 (C)
  145    *RMST*                              3394 (A)
  146    *RPS14*                             52688 (A)
  147    *RNF135*                            636 (B)
  148    *RBM15*                             519 (A)
  149    *RUNX1*                             521 (B)
  150    *RUNX1T1*                           519 (A)
  151    *SETX*                              803 (C)
  152    *STK11*                             2869 (B)
  153    *SET*                               519 (A)
  154    *NEU1*                              93448 (C)
  155    *SMAD9*                             422 (C)
  156    *SLC17A5*                           93448 (C)
  157    *SLC22A4*                           206 (C)
  158    *SLC44A4*                           93448 (C)
  159    *SOX18*                             79383 (B)
  160    *SUMF1*                             93448 (C)
  161    *SOD1*                              803 (C)
  162    *SUFU*                              3395 (A)
  163    *SUZ12*                             636 (B)
  164    *SS18*                              3394 (A)
  165    *SSX1*                              3394 (A)
  166    *SSX2*                              3394 (A)
  167    *SSX2IP*                            3394 (A)
  168    *SSX2B*                             3394 (A)
  169    *STX11*                             158032 (C)
  170    *STXBP2*                            158032 (C)
  171    *TARDBP*                            803 (C)
  172    *TEK*                               2451 (B)
  173    *TSPAN12*                           98668 (C)
  174    *THBD*                              2134(C)
  175    *TSC1*                              538 (C)
  176    *TSC2*                              538 (C)
  177    *TNFRSF10B*                         67037 (A)
  178    *UNC13D*                            158032 (C)
  179    *ABL1*                              521 (B)
  180    *VAPB*                              803 (C)
  181    *VCAN*                              98668 (C)
  182    *KRAS*                              217074 (A)
  183    *MYCN*                              3395 (A)
  184    *VWF*                               903 (C)
  185    *WT1*                               3394 (A)
  186    *ZBTB16*                            519 (A)

(A), (B), (C) correspond to subset A, B and C respectively.

###### 

Genes associated to two or more angiogenesis-related rare diseases

  *n*°   Genes       1            2            3            4            5           6         7
  ------ ----------- ------------ ------------ ------------ ------------ ----------- --------- -----------
  1      *PTEN*      3395 (A)     180250 (A)   182067 (A)   67037 (A)    201 (B)     109 (B)   65285 (A)
  2      *FUS*       3394 (A)     519 (A)      803 (C)      69078 (A)    99967 (A)             
  3      *SDHD*      180250 (A)   717 (A)      29072 (A)    201 (B)      877 (A)               
  4      *TP53*      3395 (A)     182067 (A)   360 (A)      217074 (A)   524 (A)               
  5      *CHEK2*     180250 (A)   223727 (A)   524 (A)      668 (A)                            
  6      *EWSR1*     3394 (A)     223727 (A)   319 (A)      97338 (A)                          
  7      *GBA*       355 (C)      77260 (C)    77261 (C)    85212 (C)                          
  8      *NDP*       98668 (C)    190 (C)      649 (C)      90050 (C)                          
  9      *SDHB*      180250 (A)   717 (A)      29072 (A)    201 (B)                            
  10     *TFE3*      3394 (A)     217071 (A)   151 (A)      163699 (A)                         
  11     *VHL*       217071 (A)   151 (A)      717 (A)      892 (B)                            
  12     *CFH*       279 (C)      2134 (C)     54370 (C)                                       
  13     *DMBT1*     3395 (A)     182067 (A)   360 (A)                                         
  14     *EGFR*      3395 (A)     182067 (A)   360 (A)                                         
  15     *FH*        217071 (A)   151 (A)      523 (A)                                         
  16     *GLTSCR1*   3395 (A)     182067 (A)   360 (A)                                         
  17     *GLTSCR2*   3395 (A)     182067 (A)   360 (A)                                         
  18     *GLI1*      3395 (A)     182067 (A)   360 (A)                                         
  19     *LRRN2*     3395 (A)     182067 (A)   360 (A)                                         
  20     *YEATS4*    3395 (A)     182067 (A)   360 (A)                                         
  21     *OGG1*      217071 (A)   151 (A)                                                      
  22     *ACVRL1*    422 (C)      774 (B)                                                      
  23     *APC*       3395 (A)     733 (A)                                                      
  24     *ASPSCR1*   3394 (A)     163699 (A)                                                   
  25     *AGGF1*     2346 (C)     90308 (B)                                                    
  26     *BRCA2*     180250 (A)   217074 (A)                                                   
  27     *CTNNB1*    3395 (A)     88673 (A)                                                    
  28     *COL1A1*    3394 (A)     31112 (A)                                                    
  29     *COL18A1*   98668 (C)    1571 (C)                                                     
  30     *DIRC1*     217071 (A)   151 (A)                                                      
  31     *DIRC2*     217071 (A)   151 (A)                                                      
  32     *ETV4*      223727 (A)   319 (A)                                                      
  33     *ETV1*      223727 (A)   319 (A)                                                      
  34     *FLT4*      79383 (B)    77240 (B)                                                    
  35     *FLCN*      217071 (A)   151 (A)                                                      
  36     *FHIT*      217071 (A)   151 (A)                                                      
  37     *FLI1*      223727 (A)   319 (A)                                                      
  38     *GJC2*      79383 (B)    77240 (B)                                                    
  39     *HSPBAP1*   217071 (A)   151 (A)                                                      
  40     *JAK2*      824 (B)      729 (B)                                                      
  41     *MET*       217071 (A)   88673 (A)                                                    
  42     *MEN1*      652 (B)      913 (B)                                                      
  43     *NOTCH3*    136 (C)      95509 (C)                                                    
  44     *PRCC*      217071 (A)   151 (A)                                                      
  45     *PALB2*     180250 (A)   217074 (A)                                                   
  46     *PDGFB*     3394 (A)     31112 (A)                                                    
  47     *RASA1*     2346 (C)     137667 (A)                                                   
  48     *RET*       717 (A)      1332 (A)                                                     
  49     *RNF139*    217071 (A)   151 (A)                                                      
  50     *SMAD4*     217074 (A)   774 (B)                                                      
  51     *SDHAF2*    717 (A)      29072 (A)                                                    
  52     *SDHA*      717 (A)      29072 (A)                                                    
  53     *SDHC*      717 (A)      29072 (A)                                                    
  54     *SMARCA4*   3394 (A)     69077 (A)                                                    
  55     *SMARCB1*   3394 (A)     69077 (A)                                                    
  56     *TMEM127*   717 (A)      29072 (A)                                                    
  57     *ERG*       223727 (A)   319 (A)                                                      
  58     *KIT*       44890 (A)    98292 (A)                                                    

(A), (B), (C) correspond to subset A, B and C respectively.

In the case of drugs, in this study 285 entrances were manually identified in Orphanet database as orphan drugs. As in the case of genes, three categories of A-RDs where established: those currently associated to no drug, those associated to one drug, and those with two or more drugs associated. The number of drugs in each A-RD is highlighted in Table[2](#tbl2){ref-type="table"}. Furthermore, Tables S7 and S8 (Supplementary material) list all the A-RDs associated to a single or to more than a drug, respectively, identifying the corresponding related drugs by their Orpha drug IDs. As in the case of genes, the relationship A-RDs-drugs is also asymmetrical. Tables S9 and S10 list the whole set of 198 drugs associated to one A-RD and 87 drugs associated to two or more A-RDs, respectively, identifying the corresponding A-RDs by their Orpha rare disease IDs. Figure[3](#fig03){ref-type="fig"} shows the distribution of the annotated drugs grouped in two categories (those associated to one A-RD and those associated to two or more A-RDs) in the whole set and the three subsets of A-RDs.

![Relative distribution of Orphan drugs associated to angiogenesis-related rare disease. Percentages of drugs belonging to described subsets of A-RDs: A (A-RDs with cancerous phenotype in all their features), B (A-RDs with cancerous phenotype only in some of their features) and C (A-RDs without cancerous phenotype). Horizontal-axis represents the distribution of drugs in the different subsets. Color code: blue, drugs related to one A-RD; brownish, drugs related to two or more A-RDs; dark grey: total drugs related to A-RDs.](jcmm0016-2872-f3){#fig03}

Discussion of the literature search and orphanet analysis
=========================================================

Bibliographic systematic review
-------------------------------

Our bibliographic systematic review (see Fig.[1](#fig01){ref-type="fig"}) has allowed us to select 187 references (see bibliography in Supplementary material) and 180 A-RDs (that is, 180 rare diseases related with the neovascularization process, see Table[2](#tbl2){ref-type="table"}A--C). This systematic review has also made possible the extraction of a great amount of data in an exhaustive and trustworthy manner. In the present work, these extracted data could be synthetized, validated and interrelated through the use of a reproducible methodology, based in PRISMA statements [@b20],[@b21] (see PRISMA checklist in Table S1 and PRISMA flow diagram in Figure S1). When we recovered those A-RDs that are cited three or more times in our set of selected references (29 of the 180 A-RDs), we found that in most cases vascular diseases (or malformations) or angioproliferative disorders were retrieved, with the exceptions of Multicentric castleman disease (OPRPHA93686), Multiple myeloma (ORPHA29073), Primary effusion lymphoma associated with HIV infection (ORPHA99923) and Primary effusion lymphoma (ORPHA48686). Renal cell carcinoma (ORPHA217071) was the angioproliferative disease more times referenced (in fact, it is mentioned in 14 of the 187 selected references included in supplementary material).

On the other hand, a text mining analysis has been used as an automatic and independent validation of the results achieved in the systematic review. We can observe that the enriched MeSH terms of the 187 bibliographic references, obtained from the systematic review, are notably related to angiogenesis and pathological conditions (see Table[1](#tbl1){ref-type="table"}). These results of the text mining analysis confirm that our selection of the bibliography has consistent information related to angiogenesis and biological process involved in the pathogenesis. Under these conditions, more than a half of PMIDs linked to MeSH terms related to pathologies (*i.e*. Neovascularization, Pathologic, Herpesvirus 8, Macular Degeneration, Pathologic-von Hippel--Lindau Disease, lymphangioleiomyomatosis, Renal Cell Carcinoma, Hereditary Hemorrhagic Telangiectasia, Hemangioendothelioma, POEMS Syndrome, Essential osteolysis, Capillary Hemangioma Kaposi Sarcoma, Rare Diseases and Lipoid proteinosis of Urbach and Wiethe) match with those PMIDs that are linked to MeSH terms related to angiogenesis (Angiogenesis inhibitors, Vascular Endothelial Growth Factor A, Thalidomide, Vascular Endothelial Growth Factors, Angiogenic Proteins, Vascular Endothelial Growth Factor Receptors). It is interesting to note that only three PMIDs are indicated for the term called "Rare disease", which highlights the lack of identification with this type of disease in the scientific literature (see Table[1](#tbl1){ref-type="table"}).

Initial classification of angiogenesis-related rare diseases
------------------------------------------------------------

Orphanet has its own classification of rare diseases, based on a hierarchy of descriptive categories. These categories are pathological descriptions based in published scientific data and information provided by experts in the field. These pathological descriptions are referred to as manifestations along the tables presented in this work. The close relationship between angiogenesis and tumor progression was used for the initial classification of A-RDs into three differentiated subsets (see Table[2](#tbl2){ref-type="table"}). The analysis of this classification confirmed that this procedure gave rise to a consistent separation. The dominant subset was "rare neoplasias" (subset A), as expected. Concerning A-RDs included in subset B, they are mostly vascular malformations (as angiomas and hemangiomas), as well as dysplasias and hamartomas. They are non neoplastic pathologies associated to an increased risk to develop tumors. Finally, subset C included a whole array of non-tumoral rare diseases tightly related with (and, in many cases, dependent on) angiogenesis.

On the other hand, the systematic review of the collected data allowed us to detect a number of incoherencies in the Orphanet classification of rare diseases. Some of them are highlighted here: *Cerebral cavernous malformations* (ORPHA164) are rare brain vascular malformations that are also named as brain cavernous angioma. The term "angioma" showed concurrence with this and other search terms included in the three subsets, in spite of the fact that an angioma is not a tumor [@b24]. Our analysis led to include cerebral cavernous malformations (ORPHA164) within subset A, although the Orphanet classification for this disease remained undefined ("This disease will be assigned to a classification in the near future"). Furthermore, the clinical description of this disease in Orphanet was unclear enough as to make possible its inclusion in any of the other subsets (either B or C). On the other hand, ICD-10 codes this disease as Q28.3 ("Congenital malformations, deformations and chromosomal abnormalities"), as it is also the case for other angiomas (glomuvenous malformation (ORPHA83454), among others).*POEMS syndrome* (ORPHA2905) is a rare paraneoplasia that only presented concurrency with search terms in some of their classifications. However, it is a multisystemic disease in most of the cases associated to osteosclerotic myeloma. This is the main reason why it was finally included into subset A, although there were also reasons to include it into subset B. ICD-10 codes it within R16 ("Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified").*Chronic myeloid leukemia* (ORPHA521) appears included in subset B (Table[2](#tbl2){ref-type="table"}) because at the moment in which this systematic review and analysis was carried out Orphanet offered four general categories of classification (namely, classification of hematopoietic and lymphoid tumors, classification of disease with platelet number and function anomalies, Orphanet classification of rare hematological diseases and Orphanet classification of rare tumors) for this disease, one of which (namely, classification of disease with platelet number and function anomalies) had no concurrence with search terms. However, updates arranged in Orphanet after our systematic review and analysis offer only two general classification for this disease (namely, Orphanet classification of rare hematological diseases and Orphanet classification of rare tumors), which would be consistent with the inclusion of this disease within subset A. In fact, ICD-10 codes this disease as C92.1 ("Neoplasms").

These previously commented cases and others reveal the importance of establishing correct and unambiguous denominations to these diseases in databases such as Orphanet. A systematic, unambiguous classification and the actual way in which the information is documented and transmitted can help physicians during health assistance. We have also detected that ICD-10 have no code assigned for 46% (83 out of 180) of the A-RDs listed (see Tables S2--S4 in Supplementary material). The announced release of ICD-11 (which will include a systematic classification based on worldwide accepted clinical criteria) should standardize the classification of rare diseases. This undoubtedly will make it easier the documentation procedure and the curation of the collected information concerning this kind of vaguely described disorders.

It should be mentioned that several classifications of rare diseases available in Orphanet at the moment of carrying out this systematic review were deleted from Orphanet website in more recent actualizations of the site. This was the case of Orphanet classification of red cell diseases, classification of hematopoietic and lymphoid tumors and classification of disease with platelet number and function anomalies. The recent emergence of a new category in the Orphanet classification: Inherited cancer-predisposing syndrome (ORPHA140162) should also be mentioned.

As mentioned, from the 180 selected A-RDs, these 27 highlighted with an asterisk in Table[2](#tbl2){ref-type="table"} can be considered as angiogenic rare diseases. Three of them have same genetic and molecular profiles closely related to angiogenesis: Angio-osteohypertrophic syndrome (ORPHA2346), Neurofibromatosis type I (ORPHA636) and Rendu-Osler-Weber disease (ORPHA774). Orphanet also includes information about this. The other angiogenic rare diseases are pathologies whose genetic and molecular profiles are related to certain aspects of angiogenesis such as VEGF expression, anti-angiogenic therapies or related with vascular proliferation process, among others. In many of these cases further investigation is required. A problem arises with Orpha IDs that are classified in Orphanet as diseases that group other diseases. Under these conditions, since no distinction is made by Orphanet and only in some cases it is indicated correctly (*i.e*. "This term does not characterize a disease but a group of diseases. To learn about the diseases included under this term, search for in the Classifications menu"), we think that many other diseases could be retrieved. In the case of A-RDs that group other diseases, Orphanet does not only list those genes that are being shared among all diseases belonging to that category, but it also contains all the genes that are within that class of diseases. In this context, no genetic profile is identified in these categories of classification. As mentioned, a classification made in this way is useful when grouping features around a category of diseases and allows a proper allocation of patient, but it says little about its genetic and molecular profiles. No information is displayed in the summary of almost a third of these A-RDs and only two of these that group other diseases are identified (*i.e. An Orphanet summary for this disease is currently under development. However, other data related to the disease are accessible from the Additional Information menu located on the right side of this page*). The case of Brain tumor (ORPHA3395) is clearly a kind of pathology that groups other diseases. In Oprhanet it is identified as: "This disease will be assigned to a classification in the near future". For this disease, currently no list of genes, and no classification is indicated in Orphanet.

Another problem for systematic studies is also the way in which Orphanet updates and corrects its database. For instance, up to four angiogenic rare diseases were outdated in the course of our systematic review. Glioma, now called Glial tumor (ORPHA182067), does not remain associated with the gene called *PTEN*, which in its original link (MIN ID605 691) is identified as a tumor suppressor. Oligodendroglial tumor (ORPHA46484) is linked in UniProt (ID60484) too and it is just a subcategory of glial tumor. In addition, two genes are listed for Brain tumor: *PTEN* and *CTNB1*. On the other hand, two genes (*PML* and *RBM15)* were listed for Acute myeloid leukemia (ORPHA519). Currently, the symbol RBM15 (*RNA binding motif protein 15*) does not appear in Orphanet database. In Uniprot (ID Q96T37), Acute megacaryoblastic leukemia (ORPHA518) is listed as an Orphan disease.

Genes and drugs associated to angiogenesis-related rare diseases
----------------------------------------------------------------

Figure[4](#fig04){ref-type="fig"} shows frequence distributions of A-RDs taking into account the number of genes or the number of drugs to which they are related (information abstracted from Tables[4](#tbl4){ref-type="table"} and S5--S10. As Figure[4](#fig04){ref-type="fig"} shows, approximately half of A-RDs are linked to no gene and no drug. The highest percentage of A-RDs linked to two or more genes or drugs corresponds to subset A. This reflects the actual current state of knowledge in this research area, which---as expected---is much higher in neoplastic A-RDs (those included in subset A).

![Relative distribution of angiogenesis-related rare diseases associated to genes and Orphan drugs. Left panels. Up, the percentages of A-RDs associated to drugs are shown. Down, the percentages of the three described subsets associated to genes are shown. Subsets: A (angiogenesis-related rare diseases with cancerous phenotype in all their features), B (cancer-related, angiogenesis-related rare diseases with cancerous phenotype only in some of their features) and C (angiogenesis-related rare diseases without cancerous phenotype). Right panels. Up, the percentages of A-RDs associated to drugs are shown. Down, the percentages of the same three A-RDs groups described above, here associated to genes.](jcmm0016-2872-f4){#fig04}

Lysosomal storage disease with skeletal involvement (ORPHA93448) is the A-RD linked to the highest number of genes (22), but at the same time is linked to no drug. On the other hand, both Acute myeloid leukemia (ORPHA519) and Glioblastoma (ORPHA360) are the two A-RDs with the highest number of linked drugs (33 in each case), being the third and the 12th respectively according to their linked genes (see Table[2](#tbl2){ref-type="table"} and Table S6).

As Figure[2](#fig02){ref-type="fig"} shows, most of the genes are linked to only one A-RD. The majority of those genes linked to two or more A-RDs in fact are related with A-RDs of the subset A. A similar situation is found in the case of drugs (Fig.[3](#fig03){ref-type="fig"}).

*Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)---PTEN* is one of the genes with more links to A-RDs (Table[4](#tbl4){ref-type="table"}).

It is noteworthy that Orphanet updated versions used when this systematic review and analysis was carried out identified the entrance Antisense Oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) as both a gene (which is obviously false) and as a drug (see Table[3](#tbl3){ref-type="table"} and Table S9). In both cases, this entrance was linked to an only A-RD: to Neovascular glaucoma (ORPHA94058) in Table[3](#tbl3){ref-type="table"} and to Retinopathy of prematurity (ORPHA90050) in Table S9. We have maintained both entrances according to the results yielded by our systematic methodology. This highlights that this systematic approach allows for a more correct curation of the collected data. In more recent updates of Orphanet some of the detected error have been corrected.

Concluding remarks
==================

1.  The obvious great current interest in angiogenesis and in rare diseases demanded a systematic review of the current state of knowledge in the Boolean intersection of these two research areas, namely, the still not well defined set of angiogenesis-related rare diseases. The present review report contributes to satisfy such a demand.

2.  Current technology allows researchers to have access to great databases containing overwhelming amounts of data. Furthermore, there are a number of biocomputational tools that makes it easier the access, extraction and analysis of biological data contained in databases and they can enhance the molecular knowledge emerged from the systematic review results. We claim that the critical use of such tools makes possible and affordable to carry out systematic reviews of the current state of knowledge of specific research areas. These systematic reviews are aimed to add value to the classical bibliographical reviews thanks to their potential to extract new emergent information. The present systematic review on angiogenesis-related rare diseases can be considered an initial contribution in this way.

3.  Herein we propose a simple classification of angiogenesis-related rare diseases trying to discriminate the tight relationships of those linked to cancer.

4.  We have detected that both the Orphanet classification of rare diseases and the WHO International Classification of Diseases ICD-10 urgently require deep revisions and updates.

5.  Much more research is urgently needed for the identification of genes and drugs related to many angiogenesis-related rare diseases and for the exploration of new diagnostic, prognostic and therapeutic procedures.

6.  Orphanet database is a useful resource for all scientists and physicians engaged with rare diseases, as well as for patients' associations. However, form a scientific point of view, Orphanet still lacks of an actual semantic classification of rare disease. Furthermore, a deep upgrade of the scientific information contained in Orphanet is urgently required.

7.  This systematic review of available literature on angiogenesis rare diseases has ordered and connected the currently available but up to now dispersed wealth of information on the topic, as reflected by the full set of accompanying figures and tables. This information will be useful for those interested in knowing the full set of described angiogenesis-related rare diseases, and what genes and drug treatments a specific angiogenesis-related rare disease shares with other ones. In particular, this information can be a very useful start point for new, deep reviews focused on concrete angiogenic rare diseases.

8.  Taking the ordered information contained in the accompanying figures and tables of the present work as a starting point, functional enrichment and network analysis tools could be used in the near future to make predictions of new gene targets, drugs and/or treatments for some rare diseases based in their shared spectra with the full set of angiogenesis-related rare diseases herein reviewed.
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